Liver function test (LFT) values at beginning of treatment with quinacrine, while under treatment, and after treatment was stopped. Dates are all in 2014.
| Variables | Medication First Administered | Values of LFT While Patient Took Medication | Values of LFT after Medication Stopped | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/21 | 6/26 | 6/27 | 7/1 | 7/11 | 7/22 | 8/4 | 9/10 | 10/15 | |
| Protein, 6.0–8.3 g/dl | 8.0 | 8.3 | 6.7 | 7.6 | 7.9 | 6.9 | 7.3 | 7.8 | 8.4 (H) |
| Albumin, 3.5–4.9 g/dl | 4.5 | 4.4 | 3.5 | 4.0 | 4.1 | 3.9 | 4.2 | 4.5 | 5.1 (H) |
| AST, 8–30 IU/l | 26 | 629 (H) | 592 (H) | 541 (H) | 597 (H) | 474 (H) | 256 (H) | 114 (H) | 66 (H) |
| ALT, ≤ 35 IU/l | 16 | 913 (H) | 805 (H) | 781 (H) | 901 (H) | 832 (H) | 381 (H) | 150 (H) | 84 (H) |
| Alkaline phosphatase, 30–130 IU/l | 51 | 914 (H) | 809 (H) | 1172 (H) | 1646 (H) | 1471 (H) | 1083 (H) | 446 (H) | 165 (H) |
| Bilirubin, direct, 0.0–0.3 mg/dl | 8.3 (H) | 7.6 (H) | 1.8 (H) | 0.7 (H) | |||||
| Bilirubin, total, 0.2–1.2 mg/dl | 0.3 | 11.0 (H) | 9.7 (H) | 18.1 (H) | 26.5 (H) | 16.1 (H) | 8.8 (H) | 2.0 (H) | 0.9 |
AST: aspartate aminotransferase; ALT: alanine aminotransferase; H: high.